News Formal

Biotech stocks are an unappreciated way to profit from lower rates, Goldman says

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 15 min. at publisher
  • 📊 Quality Score:
  • News: 57%
  • Publisher: 72%

Jyong Biotech Ltd ニュース

Investment Strategy,Markets,Pharmacyte Biotech Inc

As investors await the Fed rate decision Wednesday afternoon, Goldman highlighted to clients an overlooked group of stocks poised to benefit from the move.

As investors await the Federal Reserve rate decision Wednesday afternoon, Goldman Sachs highlighted to clients an overlooked group of stocks poised to benefit from the move. Biotechnology stocks offer an under-the-radar and unappreciated way to profit from the central bank's looming campaign to start cutting the cost of borrowing, according to Goldman Sachs.

Rates play a larger role than growth in driving share prices in biotechnology ," Goldman told clients. Shares in many speculative, small capitalization biotech companies have an "option-like structure" that "inherently creates interest rate risk. With little to no profitability today, but expected profitability if trials are successful, biotechnology cash flows are generally long duration," Flood wrote.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 12. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Our approach to the stock market heading into the Fed's big Wednesday decisionEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
ソース: CNBC - 🏆 12. / 72 続きを読む »